Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Sexual Dysfunction, Physiological 1Non-Small Cell Lung Cancer ALK-positive 1Neuroblastoma 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Lung Neoplasms 1Lung Diseases 1Hyperlipidemias 1Eunuchism 1Erectile Dysfunction 1Brain Neoplasms 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

Blood Specimen Collection 32Surveys and Questionnaires 24Radiotherapy 12Gene Expression Profiling 12Drug Therapy 12Surgical Procedures, Operative 11Bronchoscopy 10Magnetic Resonance Spectroscopy 9Immunotherapy 9Immunohistochemistry 9Tomography, X-Ray Computed 8Specimen Handling 8Observation 8Amplified Fragment Length Polymorphism Analysis 8Polymerase Chain Reaction 7pembrolizumab 6Psychiatric Rehabilitation 6Interviews as Topic 6Carboplatin 6Thoracic Surgery, Video-Assisted 5Reverse Transcriptase Polymerase Chain Reaction 5Microarray Analysis 5Liquid Biopsy 5Chemoradiotherapy 5Bevacizumab 5durvalumab 4Therapeutics 4Paclitaxel 4Nivolumab 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Lung Neoplasms × lorlatinib × Clear all
NCT07567352 2026-05-12

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Pfizer

Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡